Oligo Synthesis Market Size, Share, Growth, and Industry Analysis, By Type ( Common Primer Synthesis,Modified Primer Synthesis ), By Application ( Biotech Company,Academic Scientific Research Institution ), Regional Insights and Forecast to 2035

Oligo Synthesis Market Overview

Global Oligo Synthesis market size is anticipated to be worth USD 767.2 million in 2026, projected to reach USD 2128.9 million by 2035 at a 12% CAGR.

The Oligo Synthesis Market is a critical segment of the life sciences and biotechnology industry, driven by increasing demand for synthetic oligonucleotides used in genomic research, diagnostics, and therapeutic development. Oligonucleotides typically range from 15 to 200 nucleotides in length, and synthesis processes rely heavily on automated DNA synthesizers capable of producing over 10,000 oligonucleotide sequences per day. In 2024, global genomic research projects exceeded 45,000 active studies, many of which require customized oligonucleotides for polymerase chain reaction (PCR) and sequencing applications.

The USA Oligo Synthesis Market represents a major hub for biotechnology research and genomic innovation. In 2024, the United States operated more than 5,000 biotechnology companies and over 1,200 academic research institutions conducting genetic studies requiring synthetic oligonucleotides. Approximately 65% of molecular diagnostics laboratories in the United States utilize custom oligonucleotide primers for PCR testing and sequencing workflows. The country conducts over 1.5 million genetic sequencing experiments annually, many of which require thousands of synthetic oligos for assay design and gene amplification.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Over 74% of genomic research laboratories rely on synthetic oligonucleotides for PCR and sequencing workflows, while 69% of biotechnology companies require custom primers for genetic amplification and 63% of diagnostic laboratories depend on oligo synthesis technologies for molecular testing.
• Major Market Restraint: Approximately 41% of research laboratories report high synthesis costs for long oligonucleotides, while 36% experience purification challenges during high-throughput synthesis and 33% report sequence error rates impacting downstream molecular biology experiments.
• Emerging Trends: Around 58% of biotechnology research projects involve CRISPR-based gene editing technologies, while 52% of genomic laboratories are adopting high-throughput oligo synthesis platforms and 47% are integrating automated DNA synthesis systems capable of producing thousands of oligos daily.
• Regional Leadership: North America contributes nearly 39% of global oligo synthesis demand, Asia-Pacific represents approximately 34%, Europe accounts for around 21%, and Middle East & Africa collectively contribute nearly 6% of global oligonucleotide synthesis activities.
• Competitive Landscape: The top 5 oligo synthesis companies control nearly 55% of global supply capacity, while the leading 2 companies account for approximately 28% of oligonucleotide production volume and nearly 35% of high-throughput synthesis platforms are concentrated in North America.
• Market Segmentation: Common primer synthesis represents nearly 62% of total oligo synthesis demand, while modified primer synthesis accounts for approximately 38%, and biotechnology companies contribute nearly 57% of global oligonucleotide consumption.
• Recent Development: Between 2023 and 2025, nearly 48% of oligo synthesis innovations focused on high-throughput DNA synthesis technologies, 42% targeted CRISPR-related oligonucleotide applications, and 36% involved improved purification technologies achieving sequence purity above 99%.

Oligo Synthesis Market Latest Trends

The Oligo Synthesis Market Trends are closely connected with advancements in genomics, gene editing, and molecular diagnostics. In 2024, more than 12 million polymerase chain reaction tests were conducted globally each month across clinical laboratories and research institutes, each requiring synthetic oligonucleotide primers typically measuring 18 to 25 nucleotides in length. The increasing demand for precision diagnostics has significantly expanded the use of oligonucleotide synthesis technologies capable of generating thousands of custom sequences daily. Automated DNA synthesizers currently achieve coupling efficiencies exceeding 99%, which enables production of oligonucleotides up to 200 nucleotides with minimal synthesis errors. Another key trend in the Oligo Synthesis Market Analysis is the rapid adoption of CRISPR-based gene editing technologies.

The demand for synthetic oligos supporting gene editing applications has increased significantly as research institutions focus on gene therapy development and functional genomics studies involving thousands of targeted DNA sequences. Many biotechnology companies now design libraries containing 100,000 or more oligonucleotide sequences for large-scale genomic screening experiments. High-throughput oligo synthesis platforms are another important development in the Oligo Synthesis Industry Analysis. Modern synthesis platforms are capable of producing more than 50,000 unique oligonucleotide sequences in a single production batch, supporting large-scale genomic studies and next-generation sequencing applications.

Oligo Synthesis Market Dynamics

The Oligo Synthesis Market Dynamics are strongly influenced by expanding genomic research, molecular diagnostics, and gene therapy development. In 2024, more than 2 million gene sequencing experiments were conducted globally, each requiring multiple synthetic oligonucleotides typically measuring 18–30 nucleotides. Over 70% of molecular biology laboratories use oligonucleotide primers for PCR amplification, while automated DNA synthesizers achieve coupling efficiencies above 99% per nucleotide addition. However, approximately 36% of laboratories report purification challenges during long oligonucleotide synthesis exceeding 100 nucleotides. Opportunities are increasing as more than 900 gene therapy clinical trials globally depend on modified oligonucleotides for antisense therapies, RNA interference, and CRISPR gene editing experiments.

DRIVER

"Rising demand for genomic research and molecular diagnostics"

The most significant driver influencing Oligo Synthesis Market Growth is the rapid expansion of genomic research and molecular diagnostic testing. In 2024, global genomic databases contained more than 3 billion DNA sequences, and research laboratories performed over 2 million gene sequencing experiments annually. Each sequencing experiment requires multiple synthetic oligonucleotide primers used for amplification and detection of genetic material. Oligonucleotides used in PCR workflows typically measure 18–30 nucleotides, while sequencing applications may require primers up to 60 nucleotides in length. Additionally, more than 12,000 rare genetic diseases have been identified globally, increasing the need for genetic testing technologies that depend heavily on custom oligonucleotide synthesis. The rapid expansion of personalized medicine research has further accelerated demand, as targeted gene analysis requires thousands of specific oligonucleotide sequences designed for genomic detection and mutation analysis.

RESTRAINT

"Complexity and cost of long oligonucleotide synthesis"

One of the key restraints affecting the Oligo Synthesis Market Outlook is the complexity associated with synthesizing long oligonucleotide sequences. While standard primers typically contain 20 to 25 nucleotides, advanced research applications may require sequences exceeding 120 nucleotides. As oligonucleotide length increases, the probability of synthesis errors also increases because each nucleotide addition must achieve coupling efficiencies above 99%. For example, synthesizing a 100-nucleotide oligo with 99% efficiency per step results in an overall yield of approximately 36% full-length product, requiring additional purification processes. Many laboratories therefore rely on high-performance liquid chromatography or gel purification systems capable of achieving sequence purity levels above 98%.

OPPORTUNITY

"Growth in personalized medicine and gene therapy"

The expansion of personalized medicine represents a major Oligo Synthesis Market Opportunity. In 2024, more than 900 gene therapy clinical trials were actively underway globally, many involving oligonucleotide-based therapies such as antisense oligonucleotides and small interfering RNA molecules. These therapeutic oligonucleotides typically range from 18 to 25 nucleotides and require precise chemical modifications to enhance stability and delivery efficiency. Pharmaceutical companies developing nucleic acid therapies often require thousands of customized oligonucleotide sequences during drug discovery and validation phases. Additionally, large-scale genomic screening experiments frequently use oligo libraries containing more than 100,000 sequences designed for gene editing and mutation analysis.

CHALLENGE

"Quality control and sequence accuracy in high-throughput synthesis"

Maintaining sequence accuracy during high-throughput oligonucleotide production is a major challenge in the Oligo Synthesis Industry Analysis. Automated DNA synthesis systems used in large research facilities may produce tens of thousands of oligonucleotides per batch, each requiring precise nucleotide addition steps. Even a small synthesis error rate of 1% per nucleotide can result in a significant number of incorrect sequences in large oligo libraries. Quality control processes therefore include analytical techniques such as mass spectrometry and capillary electrophoresis capable of detecting sequence errors with accuracy levels above 99.5%. Additionally, oligonucleotide synthesis facilities must maintain controlled environmental conditions including humidity levels below 40% and temperature ranges between 20°C and 25°C to ensure consistent chemical reactions during synthesis cycles. These stringent quality requirements increase production complexity in large-scale oligonucleotide manufacturing environments.

Oligo Synthesis Market Segmentation

The Oligo Synthesis Market segmentation is primarily categorized by type and application, reflecting the wide range of genomic and molecular biology research activities that depend on synthetic oligonucleotides. By type, the market is divided into Common Primer Synthesis and Modified Primer Synthesis, both widely used in genetic analysis, PCR testing, sequencing, and gene editing workflows. Common primer synthesis contributes nearly 62% of total oligonucleotide production, as standard primers between 18 and 30 nucleotides are required for most polymerase chain reaction assays. Modified primer synthesis accounts for approximately 38%, driven by the growing demand for chemically modified oligonucleotides used in diagnostics and therapeutics. By application, biotechnology companies represent about 57% of total demand, while academic scientific research institutions contribute around 43% of oligonucleotide consumption globally.

Download Free Sample to learn more about this report.

By Type

Common Primer Synthesis: Common primer synthesis represents nearly 62% of the Oligo Synthesis Market Share, primarily due to its extensive use in polymerase chain reaction assays and DNA sequencing applications. Standard oligonucleotide primers typically range between 18 and 30 nucleotides, with melting temperatures generally maintained between 55°C and 65°C for efficient DNA amplification. In 2024, more than 12 million PCR reactions were conducted globally every day, and each PCR experiment required at least 2 synthetic oligonucleotide primers for amplification. Automated oligonucleotide synthesizers can generate up to 10,000 primer sequences within a single production cycle, enabling rapid supply for research laboratories and diagnostic facilities. Common primer synthesis also supports next-generation sequencing workflows, which require thousands of short oligonucleotides for DNA library preparation. Modern genomic laboratories performing sequencing analysis often use primer pools containing 1,000 to 10,000 individual oligonucleotide sequences for targeted genomic studies.

Modified Primer Synthesis: Modified primer synthesis accounts for approximately 38% of the Oligo Synthesis Market Size, driven by growing applications in therapeutics, diagnostics, and advanced molecular biology research. Modified oligonucleotides incorporate chemical modifications such as fluorescent labels, biotin tags, phosphorothioate linkages, and locked nucleic acid structures to improve stability and detection capabilities. These modified primers typically range between 20 and 60 nucleotides and are widely used in gene expression analysis, mutation detection, and molecular diagnostics. In 2024, more than 35% of genomic diagnostic assays incorporated modified oligonucleotides for improved sensitivity and specificity. Fluorescently labeled primers used in real-time PCR assays enable detection of DNA amplification signals within 30 to 40 amplification cycles, improving diagnostic accuracy for viral and bacterial pathogens.

By Application

Biotech Company: Biotechnology companies represent approximately 57% of the Oligo Synthesis Market Share, as these organizations conduct large-scale genomic research, drug discovery, and diagnostic assay development requiring significant volumes of synthetic oligonucleotides. In 2024, more than 8,000 biotechnology firms globally were actively engaged in genetic research projects involving synthetic DNA sequences. Each biotechnology research program may require thousands of custom oligonucleotides annually for gene cloning, mutation analysis, and sequencing experiments. Biotech companies also rely heavily on oligonucleotide libraries containing 10,000 to 100,000 sequences for high-throughput genomic screening experiments. For example, CRISPR-based gene editing studies frequently utilize guide RNA oligonucleotides measuring 20 nucleotides, enabling researchers to target specific genomic regions with high precision. Pharmaceutical biotechnology companies conducting nucleic acid drug development require synthetic oligonucleotides with sequence purities above 98%, ensuring accurate therapeutic testing in clinical research.

Academic Scientific Research Institution: Academic scientific research institutions contribute approximately 43% of Oligo Synthesis Market demand, driven by large-scale genomic research programs and academic collaborations studying genetic diseases and molecular biology processes. Globally, more than 10,000 universities and research institutes conduct life science research requiring synthetic oligonucleotides for laboratory experiments. Academic laboratories perform millions of PCR reactions annually, each requiring at least 2 custom primers designed for specific DNA sequences. University research centers involved in genome sequencing projects often analyze organisms with genomes containing millions to billions of base pairs, requiring thousands of synthetic oligonucleotides for sequencing and analysis. For instance, large-scale genomic projects studying microbial genomes may involve primer libraries containing 500 to 5,000 oligonucleotide sequences used for amplification and gene identification.

Regional Outlook for the Oligo Synthesis Market

The Oligo Synthesis Market Regional Outlook highlights strong demand across biotechnology and genomic research hubs worldwide. North America accounts for nearly 39% of global oligonucleotide synthesis activities, supported by over 5,000 biotechnology companies and 1,200 research institutions. Asia-Pacific holds around 34%, driven by more than 4,500 biotechnology firms and increasing genomic medicine programs across China, Japan, and South Korea. Europe contributes approximately 21%, supported by 3,000 biotechnology companies and over 900 research institutes conducting DNA sequencing studies. Middle East & Africa represent nearly 6%, where more than 120 biotechnology research centers perform genetic sequencing experiments and molecular diagnostics requiring synthetic oligonucleotide primers.

Download Free Sample to learn more about this report.

North America

North America represents approximately 39% of the Oligo Synthesis Market Share, making it the largest regional contributor to global oligonucleotide demand. The region hosts more than 5,000 biotechnology companies and over 1,200 life science research institutions engaged in genomic studies requiring synthetic DNA sequences. In 2024, North American laboratories conducted more than 500,000 genetic sequencing experiments, each requiring dozens of custom oligonucleotide primers for DNA amplification and analysis. The United States dominates the regional market with more than 70 major genomic research centers and hundreds of molecular diagnostics laboratories performing PCR-based testing. PCR experiments performed in the region exceed 5 million tests per month, generating consistent demand for oligonucleotide primers measuring 18–25 nucleotides. Additionally, North America leads in gene therapy research with more than 400 active clinical trials involving nucleic acid therapeutics that require modified oligonucleotides for drug development. Advanced DNA synthesis technologies are also widely used in North America, where automated synthesis platforms can generate 10,000 to 50,000 oligonucleotide sequences per production cycle. Pharmaceutical research laboratories developing RNA interference therapies and antisense oligonucleotide drugs require sequences with purities above 98%, increasing the importance of high-quality synthesis and purification technologies across the region.

Europe

Europe holds approximately 21% of the Oligo Synthesis Market Size, supported by a strong network of biotechnology research institutions and pharmaceutical development centers. The region operates more than 3,000 biotechnology companies and over 900 academic research institutes conducting molecular biology research that relies on synthetic oligonucleotides. European genomic research programs involve extensive DNA sequencing activities, with laboratories performing more than 200,000 sequencing experiments annually. Each sequencing workflow requires multiple synthetic oligonucleotides for amplification and library preparation. European pharmaceutical companies developing nucleic acid therapeutics also require large quantities of modified oligonucleotides measuring 18–25 nucleotides, supporting research into treatments for genetic diseases. In addition, Europe has become a major hub for CRISPR gene editing research, with more than 1,200 research laboratories conducting gene editing experiments. These laboratories frequently synthesize guide RNA sequences containing 20 nucleotides, enabling targeted modification of genomic DNA. European molecular diagnostics laboratories also rely heavily on oligonucleotide primers for pathogen detection, performing more than 2 million PCR tests annually across clinical laboratories.

Asia-Pacific

Asia-Pacific accounts for approximately 34% of the Oligo Synthesis Market Share, making it the second-largest regional contributor to global oligonucleotide demand. Countries including China, Japan, South Korea, and India have rapidly expanded biotechnology research capabilities, with more than 4,500 biotechnology companies operating across the region. China alone hosts more than 2,000 life science research institutes performing genomic studies requiring custom oligonucleotide synthesis. In 2024, Asia-Pacific laboratories conducted more than 300,000 DNA sequencing experiments, many of which required primer libraries containing hundreds or thousands of oligonucleotide sequences. The region also has a rapidly growing pharmaceutical research sector focused on nucleic acid therapeutics, including antisense oligonucleotides and RNA interference molecules typically measuring 18–25 nucleotides. Additionally, Asia-Pacific countries have invested heavily in genomic medicine initiatives involving population-scale genetic analysis. These programs often require oligonucleotide libraries containing 10,000 or more sequences used in targeted sequencing panels for disease detection. Biotechnology companies in the region also operate high-throughput synthesis platforms capable of producing 50,000 oligonucleotides per batch, supporting large genomic research projects and clinical diagnostics development.

Middle East & Africa

The Middle East & Africa region represents approximately 6% of the Oligo Synthesis Market, supported by emerging biotechnology research programs and growing investments in molecular diagnostics. Countries including Israel, the United Arab Emirates, and South Africa have established more than 120 biotechnology research centers focusing on genomic medicine and molecular biology research. Israel is a leading biotechnology hub within the region, hosting over 80 biotechnology companies involved in genetic research and drug development. Research institutions in the Middle East & Africa conduct more than 20,000 genetic sequencing experiments annually, many requiring synthetic oligonucleotides for amplification and mutation analysis. Medical diagnostics laboratories across the region perform PCR-based disease detection tests that rely on oligonucleotide primers typically measuring 20 nucleotides. These laboratories conduct over 500,000 diagnostic tests annually, generating steady demand for custom oligonucleotide synthesis services. Additionally, governments in several Middle Eastern countries have launched genomic medicine initiatives aimed at analyzing the genetic profiles of hundreds of thousands of individuals, which requires large numbers of synthetic oligonucleotide sequences for sequencing and genetic analysis workflows.

List of Top Oligo Synthesis Companies

• Thermo Fisher Scientific
• Merck
• Azenta Life Sciences
• BBI Life Sciences
• TriLink BioTechnologies
• Aurigene Pharmaceutical Services
• Integrated DNA Technologies (IDT)
• Cusabio
• Macrogen
• Synbio Technologies
• Eurogentec
• Genscript
• Abace Biotechnology
• Tsingke
• Guangzhou RiboBio
• Atantares
• Wuhan GeneCreate Biological Engineering
• Beyotime
• General Biol
• Biosune

Thermo Fisher Scientific: holds approximately 16% of the global Oligo Synthesis Market Share, supported by extensive oligonucleotide manufacturing infrastructure and advanced DNA synthesis technologies. The company operates more than 50 research and production facilities worldwide and supplies synthetic oligonucleotides to over 150 countries. Its high-throughput synthesis platforms can generate more than 100,000 oligonucleotide sequences per production cycle, supporting genomic research projects, CRISPR experiments, and molecular diagnostics workflows.

Merck: accounts for approximately 12% of the Oligo Synthesis Market Share, positioning it as another major global supplier of synthetic oligonucleotides. The company provides custom oligonucleotide synthesis services capable of producing sequences with purities above 98%, supporting pharmaceutical research and genomic testing laboratories. Merck operates more than 40 life science manufacturing facilities globally, many equipped with automated DNA synthesizers capable of generating thousands of oligonucleotide primers daily.

Investment Analysis and Opportunities

The Oligo Synthesis Market Opportunities are expanding rapidly as biotechnology companies, pharmaceutical manufacturers, and research institutions increase investments in genomic research and nucleic acid therapeutics. In 2024, more than 2,000 biotechnology investment projects focused on genetic technologies and synthetic biology research were recorded globally. These initiatives frequently require high-volume oligonucleotide synthesis to support gene sequencing, CRISPR experiments, and diagnostic assay development. Each genomic research program may require thousands to tens of thousands of oligonucleotide sequences, particularly when designing targeted sequencing panels or guide RNA libraries for gene editing experiments. Investments in automated DNA synthesis technology are also increasing significantly. Modern synthesis platforms can produce more than 50,000 unique oligonucleotide sequences in a single synthesis cycle, enabling high-throughput genomic research programs that analyze thousands of genes simultaneously.

Pharmaceutical companies developing nucleic acid therapeutics are another major source of investment. In 2024, more than 900 clinical trials globally investigated gene therapy or RNA-based treatments that rely on synthetic oligonucleotides measuring 18–25 nucleotides. Additionally, national genomic medicine programs across more than 30 countries are conducting large-scale population sequencing projects involving hundreds of thousands of DNA samples. Each sequencing workflow requires multiple oligonucleotide primers for amplification and analysis, significantly increasing demand for large-scale synthesis technologies. Investments in advanced purification systems capable of achieving sequence purity above 99% are also expanding as pharmaceutical and clinical research programs require highly accurate oligonucleotide sequences for therapeutic development.

New Product Development

Innovation in the Oligo Synthesis Market is centered on improving synthesis efficiency, sequence accuracy, and large-scale oligonucleotide production capacity. Modern DNA synthesis technologies now achieve coupling efficiencies above 99.5% per nucleotide addition, enabling production of longer oligonucleotide sequences exceeding 200 nucleotides with minimal synthesis errors. These advancements are particularly important for synthetic biology applications where complex DNA constructs require multiple oligonucleotides assembled into larger genetic sequences. Another major innovation area involves high-throughput oligonucleotide library synthesis, which allows researchers to produce thousands of unique sequences simultaneously. Advanced synthesis platforms introduced in recent years can generate 100,000 oligonucleotides in a single production batch, supporting genomic screening experiments that analyze large gene libraries. These oligonucleotide libraries are widely used in CRISPR gene editing experiments where guide RNA sequences measuring 20 nucleotides are synthesized for targeted genomic modifications.

Fluorescently labeled and chemically modified oligonucleotides are also an important area of product development. Modified primers used in quantitative PCR assays contain fluorescent tags capable of detecting DNA amplification signals within 30 amplification cycles, enabling rapid pathogen detection in molecular diagnostics laboratories. Additionally, new chemical modifications such as phosphorothioate backbones and locked nucleic acids improve oligonucleotide stability, allowing synthetic sequences to remain active in biological environments for 24–72 hours during therapeutic research experiments. Manufacturers are also developing improved purification technologies capable of achieving sequence purities exceeding 99%, which is essential for pharmaceutical applications involving antisense oligonucleotides and RNA interference molecules. These innovations are significantly improving the accuracy and reliability of synthetic DNA production across biotechnology and medical research industries.

Five Recent Developments

• In 2023, Thermo Fisher Scientific introduced a high-throughput oligonucleotide synthesis platform capable of producing more than 120,000 unique oligonucleotide sequences in a single production cycle, supporting large genomic screening projects.
• In 2023, Merck expanded its oligonucleotide manufacturing infrastructure by increasing automated synthesis capacity capable of producing tens of thousands of primers daily for PCR diagnostics and genomic research laboratories.
• In 2024, Integrated DNA Technologies introduced an advanced purification system capable of achieving oligonucleotide sequence purity above 99.2%, improving reliability for nucleic acid therapeutic development.
• In 2024, TriLink BioTechnologies launched chemically modified oligonucleotides designed for RNA-based therapeutics with sequence lengths between 18 and 25 nucleotides, supporting research into genetic disease treatments.
• In 2025, GenScript introduced a large-scale oligonucleotide library synthesis service capable of generating more than 100,000 unique sequences per batch, enabling high-throughput CRISPR screening experiments.

Report Coverage of Oligo Synthesis Market

The Oligo Synthesis Market Research Report provides comprehensive insights into global demand for synthetic oligonucleotides used in biotechnology research, molecular diagnostics, and nucleic acid therapeutics. The report analyzes key industry segments including common primer synthesis and modified primer synthesis, along with major applications across biotechnology companies and academic research institutions. Synthetic oligonucleotides typically range between 15 and 200 nucleotides, and the report examines how different sequence lengths influence synthesis efficiency, purification requirements, and research applications. The Oligo Synthesis Market Analysis also evaluates global genomic research activity, which involves more than 45,000 active genetic studies and millions of PCR tests conducted annually. These experiments require custom oligonucleotide primers typically measuring 18–25 nucleotides for DNA amplification and sequencing analysis.

The report further examines advanced technologies such as automated DNA synthesis systems capable of generating 10,000 to 50,000 oligonucleotide sequences per production cycle, supporting high-throughput genomic research programs. In addition, the Oligo Synthesis Industry Report provides regional insights covering North America, Europe, Asia-Pacific, and the Middle East & Africa, highlighting how biotechnology infrastructure and genomic research capacity influence oligonucleotide demand. The report also analyzes technological innovations including CRISPR gene editing oligonucleotides, antisense therapeutic sequences, and large-scale oligonucleotide libraries containing more than 100,000 sequences used in genomic screening experiments. These analytical insights provide detailed coverage of the evolving oligonucleotide synthesis industry and its role in modern biotechnology and medical research.